Prime Medicine, Inc. – NASDAQ:PRME

Add to watchlist

$3.252

+0.35

+12.14%

Market closed

Open in 2 days

-49.21%

month

-49.21%

quarter

-69.18%

year

Market Cap	366.59M
Enterprise value	779.65M

P/E	-3.08
EV/Sales	N/A
EV/EBITDA	-12.21
Price/Sales	N/A
Price/Book	4.17
PEG ratio	N/A
EPS	-2.13

Revenue	N/A
EBITDA	-194.48M
Income	-204.49M
Revenue Q/Q	N/A
Revenue Y/Y	404.47%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Prime Medicine, Inc. (NASDAQ:PRME): Profit margin
Jun 2023	0	-42.38M
Sep 2023	0	-50.70M
Dec 2023	25.69M	-65.64M	-255.5%
Mar 2024	591K	-45.76M	-7742.98%

Prime Medicine Financials Estimate

Q Y

Prime Medicine, Inc. (NASDAQ:PRME): Analyst Estimates
Mar 2024	591K	-45.76M	-7742.98%
Sep 2025	0	-41.87M
Oct 2025	208.95K	-37.25M	-17831.99%
Dec 2025	175.70K	-37.25M	-21205.97%

Analysts Price target
Financials & Ratios estimates

Prime Medicine, Inc. (NASDAQ:PRME): Earnings per share (EPS)
2023-03-09	-0.48059	-0.56

Prime Medicine, Inc. (NASDAQ:PRME): Debt to assets
Jun 2023	280865000	40.76M	14.51%
Sep 2023	239145000	45.18M	18.9%
Dec 2023	193851000	60.78M	31.35%
Mar 2024	311383000	67.61M	21.72%

Prime Medicine, Inc. (NASDAQ:PRME): Cash Flow
Jun 2023	-40.82M	27.86M	75K
Sep 2023	-39.16M	-37.77M	318K
Dec 2023	-43.86M	41.28M	194K
Mar 2024	-67.70M	-37.03M	157.32M

Prime Medicine alternative data

Prime Medicine, Inc. (NASDAQ:PRME): Employee count
Aug 2023	175
Sep 2023	175
Oct 2023	175
Nov 2023	175
Dec 2023	175
Jan 2024	175
Feb 2024	175
Mar 2024	234
Apr 2024	234
May 2024	234
Jun 2024	234
Jul 2024	234

Prime Medicine
Hedge Funds Holdings Q1 2023

88.62% -11.38%

of PRME is owned by hedge funds

38 -27

hedge funds hold PRME stock

30.03M -11.28M

shares is hold by hedge funds

PRME hedge funds holdings changes

Prime Medicine
Insider Trading

Prime Medicine, Inc. (NASDAQ:PRME): Insider trades (number of shares)
Period	Buy	Sel
May 2023	0	1086196
Jun 2023	0	335994
Feb 2024	9600000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	15 Feb 2024	NELSEN ROBERT director, 10 percent owner: director, 10 percent owner:	Common Stock	3,200,000	$6.25	$20,000,000
Purchase	15 Feb 2024	ARCH VENTURE PARTNERS XII, LLC 10 percent owner 10 percent owner	Common Stock	3,200,000	$6.25	$20,000,000
Purchase	15 Feb 2024	ARCH VENTURE PARTNERS X, LLC 10 percent owner 10 percent owner	Common Stock	3,200,000	$6.25	$20,000,000
Sale	21 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	19,003	$14.97	$284,494
Sale	20 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	37,405	$15.06	$563,244
Sale	16 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	6,532	$15.02	$98,111
Sale	15 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	66,659	$14.92	$994,352
Sale	14 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	28,960	$14.87	$430,693
Sale	13 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	28,100	$15.13	$425,097
Sale	12 Jun 2023	GV 2019 GP, L.L.C. 10 percent owner 10 percent owner	Common Stock	16,031	$14.98	$240,144

PRME insider trading transactions

Prime Medicine
Latest News

Tuesday, 26 November 2024
05:10	Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies	seekingalpha.com
Thursday, 21 November 2024
04:18	Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics	globenewswire.com
Wednesday, 6 November 2024
16:00	Prime Medicine to Participate in Upcoming Investor Conferences	globenewswire.com
Monday, 28 October 2024
10:00	12 High-Growth Stocks That Could Deliver Parabolic Returns	fool.com
Thursday, 24 October 2024
08:00	Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress	globenewswire.com
Wednesday, 16 October 2024
09:45	Why I Keep Buying These 14 Incredible Growth Stocks	fool.com
Tuesday, 15 October 2024
08:00	Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings	globenewswire.com
Tuesday, 1 October 2024
15:46	PRME Stock Rises 11.8% on Collaboration With Bristol Myers	zacks.com
15:19	Got $100? Consider Buying These 2 Penny Stocks in October	247wallst.com
Monday, 30 September 2024
18:08	Why Prime Medicine Stock Soared Nearly 12% Higher on Monday	fool.com
12:17	Crude Oil Moves Higher; Prime Medicine Shares Spike Higher	benzinga.com
08:38	Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline	benzinga.com
07:01	Prime Medicine Unveils Strategically Focused Pipeline	globenewswire.com
Wednesday, 28 August 2024
08:15	2 Growth Stocks That Could Make You Richer	fool.com
Wednesday, 31 July 2024
14:57	Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?	zacks.com
Friday, 19 July 2024
11:00	Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?	zacks.com
Friday, 21 June 2024
09:25	Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio	zacks.com
Thursday, 30 May 2024
10:55	Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade	zacks.com
Wednesday, 29 May 2024
06:30	If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names	investorplace.com
Saturday, 25 May 2024
04:10	Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio	fool.com
Friday, 17 May 2024
06:27	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024	investorplace.com
06:15	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024	investorplace.com
Tuesday, 14 May 2024
10:56	Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?	Zacks Investment Research
Monday, 13 May 2024
08:00	Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	GlobeNewsWire
Friday, 3 May 2024
13:01	What Makes Prime Medicine, Inc. (PRME) a New Buy Stock	Zacks Investment Research
Tuesday, 23 April 2024
08:00	Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings	GlobeNewsWire
Wednesday, 27 March 2024
08:45	2 Magnificent Growth Stocks With Room to Run	The Motley Fool
Thursday, 14 March 2024
14:44	Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging	InvestorPlace
Friday, 1 March 2024
14:00	Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?	InvestorPlace
Wednesday, 28 February 2024
08:00	Prime Medicine to Participate in Upcoming Investor Conferences	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 7 Jul 2025

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
Seeking Alpha 28 Jan 2024

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Seeking Alpha 1 Dec 2023

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?
Seeking Alpha 27 Sep 2023

Prime Medicine: Not Yet Primed For Retail Investment
Seeking Alpha 23 Apr 2023

Prime Medicine: Gene Editing Tech With Unique Approach
Seeking Alpha 12 Jan 2023

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics
Seeking Alpha 4 Jan 2023

10 Potential 10x Return Stocks For The Next 10 Years
Seeking Alpha 24 Oct 2022

Prime Medicine: CRISPR 3.0 Company

Frequently Asked Questions (FAQ)

What's the price of Prime Medicine stock today?

One share of Prime Medicine stock can currently be purchased for approximately $3.25.
When is Prime Medicine's next earnings date?

Unfortunately, Prime Medicine's (PRME) next earnings date is currently unknown.
Does Prime Medicine pay dividends?

No, Prime Medicine does not pay dividends.
How much money does Prime Medicine make?

Prime Medicine has a market capitalization of 366.59M. Prime Medicine made a loss 198.13M US dollars in net income (profit) last year or -$0.56 on an earnings per share basis.
What is Prime Medicine's stock symbol?

Prime Medicine, Inc. is traded on the NASDAQ under the ticker symbol "PRME".
What is Prime Medicine's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Prime Medicine?

Shares of Prime Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Prime Medicine have?

As Jul 2024, Prime Medicine employs 234 workers.
When Prime Medicine went public?

Prime Medicine, Inc. is publicly traded company for more then 2 years since IPO on 20 Oct 2022.
What is Prime Medicine's official website?

The official website for Prime Medicine is primemedicine.com.
Where are Prime Medicine's headquarters?

Prime Medicine is headquartered at 21 Erie Street, Cambridge, MA.
How can i contact Prime Medicine?

Prime Medicine's mailing address is 21 Erie Street, Cambridge, MA and company can be reached via phone at +61 75640013.

Prime Medicine, Inc.

primemedicine.com

Exchange:

NASDAQ

Full time employees:

234

Industry:

Biotechnology

Sector:

Healthcare

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

+61 75640013

21 Erie Street
Cambridge, MA 02139

CIK: 0001894562
ISIN: US74168J1016
CUSIP: 74168J101